Abstract
Hepatocellular carcinoma (HCC) is a global health problem and responsible for up to 500.000 deaths annually. It usually occurs secondary to infections with hepatitis B or C viruses, alcohol consumption, non-alcoholic steatohepatitis or hereditary liver diseases. The prognosis for patients with advanced disease is dismal; therefore, new strategies to prevent or treat this malignancy are urgently needed. Over recent years, several molecular pathways have been identified contributing to the molecular pathogenesis of this devastating disease, among them the PI3K/AKT/mTOR pathway. mTOR is effectively inhibited by rapamycin and its derivatives such as temsirolimus and everolimus. The anti-tumor activity of rapamycin was identified more than 30 years ago in a screen performed at the National Cancer Institute, but was subsequently not developed for cancer treatment. In the 1990s, activation of the mTOR pathway was recognized in various malignancies spurring again the interest in mTOR inhibitors for anti-cancer treatment. In 2007, the US Food and Drug Administration approved the first mTOR inhibitor, temsirolimus, for the treatment of renal cell carcinoma. Currently, several clinical studies are underway to define the role of mTOR inhibitors for the treatment of hepatocellular carcinoma. The aim of this review is to outline the role of mTOR for hepatocarcinogenesis. We will also discuss the latest preclinical and clinical data of mTOR inhibitors for the prevention and treatment of HCC.
Keywords: Hepatocellular Carcinoma, mTOR, rapamycin, RAD001, Eukaryotic Translation Initiation Factor 4E- Binding Protein 1, Fumarylacetoacetate, Fumarylacetoacetate Hydrolase, Hepatitis B Virus, Hepatitis C Virus, Hypoxia-Inducible Factor-1, Hereditary Tyrosinemia type 1, Mammalian Target of Rapamycin, mTOR Complex 1, Phosphoinositide-3 Kinase, Vascular Endothelial Growth Factor
Current Cancer Drug Targets
Title:mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma
Volume: 12 Issue: 9
Author(s): Laura Elisa Buitrago-Molina and Arndt Vogel
Affiliation:
Keywords: Hepatocellular Carcinoma, mTOR, rapamycin, RAD001, Eukaryotic Translation Initiation Factor 4E- Binding Protein 1, Fumarylacetoacetate, Fumarylacetoacetate Hydrolase, Hepatitis B Virus, Hepatitis C Virus, Hypoxia-Inducible Factor-1, Hereditary Tyrosinemia type 1, Mammalian Target of Rapamycin, mTOR Complex 1, Phosphoinositide-3 Kinase, Vascular Endothelial Growth Factor
Abstract: Hepatocellular carcinoma (HCC) is a global health problem and responsible for up to 500.000 deaths annually. It usually occurs secondary to infections with hepatitis B or C viruses, alcohol consumption, non-alcoholic steatohepatitis or hereditary liver diseases. The prognosis for patients with advanced disease is dismal; therefore, new strategies to prevent or treat this malignancy are urgently needed. Over recent years, several molecular pathways have been identified contributing to the molecular pathogenesis of this devastating disease, among them the PI3K/AKT/mTOR pathway. mTOR is effectively inhibited by rapamycin and its derivatives such as temsirolimus and everolimus. The anti-tumor activity of rapamycin was identified more than 30 years ago in a screen performed at the National Cancer Institute, but was subsequently not developed for cancer treatment. In the 1990s, activation of the mTOR pathway was recognized in various malignancies spurring again the interest in mTOR inhibitors for anti-cancer treatment. In 2007, the US Food and Drug Administration approved the first mTOR inhibitor, temsirolimus, for the treatment of renal cell carcinoma. Currently, several clinical studies are underway to define the role of mTOR inhibitors for the treatment of hepatocellular carcinoma. The aim of this review is to outline the role of mTOR for hepatocarcinogenesis. We will also discuss the latest preclinical and clinical data of mTOR inhibitors for the prevention and treatment of HCC.
Export Options
About this article
Cite this article as:
Elisa Buitrago-Molina Laura and Vogel Arndt, mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091045
DOI https://dx.doi.org/10.2174/15680096112091045 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer
Current Pharmaceutical Design Ion Transporters in Brain Tumors
Current Medicinal Chemistry Editorial [Hot Topic: PET and SPECT in Drug Evaluation and Drug Design Imaging Inflammatory Processes, Tumors, and the Endocannabinoid System(Executive Editor: Aren van Waarde)]
Current Pharmaceutical Design In Memory of Dr. Herbert E. Nieburgs – Ex-Associate Editor of CCDT
Current Cancer Drug Targets Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Magnetic Carriers: A Promising Device for Targeting Drugs Into the Human Body
Current Pharmaceutical Design COMMENTARY: Pre-emptive Nutrition: Refining the Targets of Drugs Targeted to Colorectal Cancer
Current Cancer Drug Targets Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics
Current Topics in Medicinal Chemistry Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Microaspiration in Intubated Critically Ill Patients: Diagnosis and Prevention
Infectious Disorders - Drug Targets Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Polymorphisms of Genes Encoding Phase I Enzymes in Mexican Americans – An Ethnic Comparison Study
Current Pharmacogenomics Meet Our Editorial Board Member
Current Cancer Drug Targets Meet Our Editor:
MicroRNA Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Differential Network Analysis in Human Cancer Research
Current Pharmaceutical Design Gold Nanoparticle-Based Drug Delivery Platform for Antineoplastic Chemotherapy
Current Drug Metabolism Cell Penetrating Peptides and the Mechanisms for Intracellular Entry
Current Pharmaceutical Biotechnology Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews